Skip to Content
Merck

R3530

Rifabutin

>98% (HPLC), powder, antibiotic

Synonym(s):

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

5 MG

1 500,00 kr

25 MG

5 500,00 kr

1 500,00 kr

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C46H62N4O11
CAS Number:
72559-06-9
Molecular Weight:
847.00
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Rifabutin, >98% (HPLC), powder

SMILES string

[N+H]1(CCC2(NC3=C4NC(=O)\C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](\C=C\O[C@]5(Oc6c(c(c(c(c6C)[O-])C4=O)C3=N2)C5=O)C)OC)C)OC(=O)C)C)O)C)O)C)\C)CC1)CC(C)C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

InChI key

ATEBXHFBFRCZMA-VXTBVIBXSA-N

assay

>98% (HPLC)

form

powder

storage condition

protect from light

solubility

DMSO: >5 mg/mL

antibiotic activity spectrum

neoplastics

mode of action

enzyme | inhibits

originator

Johnson & Johnson

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
1603800Y0000149PHR2611
Rifabutin >98% (HPLC), powder

Sigma-Aldrich

R3530

Rifabutin

USP

USP

1603800

Rifabutin

vibrant-m

Y0000149

Rifabutin

Rifabutin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2611

Rifabutin

form

powder

form

-

form

-

form

solid

assay

>98% (HPLC)

assay

-

assay

-

assay

-

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

300

storage temp.

−20°C

storage temp.

-

storage temp.

2-8°C

storage temp.

-10 to -25°C

storage condition

protect from light

storage condition

-

storage condition

-

storage condition

-

solubility

DMSO: >5 mg/mL

solubility

-

solubility

-

solubility

-

Biochem/physiol Actions

Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.
Rifabutin is an antibiotic; antitumor.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000503364
0000503363
0000503363
0000503364
0000426240

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J P Gisbert et al.
Alimentary pharmacology & therapeutics, 35(8), 941-947 (2012-03-01)
In some cases, Helicobacter pylori infection persists even after three eradication treatments. To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. Multicentre, prospective study. In whom the following three treatments had
C Y Tay et al.
Alimentary pharmacology & therapeutics, 36(11-12), 1076-1083 (2012-10-18)
Helicobacter pylori eradication rates with standard triple therapy are declining worldwide. The optimal management of H. pylori is evolving and new treatment combinations for antibiotic resistant H. pylori strains are required, especially for patients with penicillin allergy. To review the
Jakko van Ingen et al.
American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)
Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug
Matthew D Hickey et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(4), 457-461 (2013-03-26)
Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from
Kelly E Dooley et al.
Journal of acquired immune deficiency syndromes (1999), 62(1), 21-27 (2012-10-19)
Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service